Protagonist Therapeutics, Inc (PTGX) Earnings
Protagonist Therapeutics, Inc's most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Nov 5, 2026
From the latest earnings 8-K
Revenue • FY2025
$46.02M
▼ 89.4%YoY
Diluted EPS • FY2025
-$2.05
▼ 148.5%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from PTGX's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $46.02M | -$130.15M | — | -$2.05 | $56.08M | -343.6% | -89.4% |
| FY2024 | $434.43M | $275.19M | — | $4.23 | $182.8M | 58.2% | +624.1% |
| FY2023 | $60M | -$78.95M | — | -$1.39 | -$70.84M | -156.1% | +125.7% |
| FY2022 | $26.58M | -$127.39M | — | -$2.60 | -$108.93M | -494.2% | -2.8% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Nov 5, 2026 | 8-K (2.02) | 0001104659-26-123351EDGAR |
| Aug 5, 2026 | 8-K (2.02) | 0001104659-26-091099EDGAR |
| May 5, 2026 | 8-K (2.02) | 0001104659-26-055629EDGAR |
| Feb 25, 2026 | 8-K (2.02) | 0001104659-26-019658EDGAR |
| Nov 6, 2025 | 8-K (2.02) | 0001104659-25-107753EDGAR |
| Aug 6, 2025 | 8-K (2.02) | 0001104659-25-074719EDGAR |
| May 6, 2025 | 8-K (2.02) | 0001104659-25-045073EDGAR |
| Feb 21, 2025 | 8-K (2.02) | 0001104659-25-015897EDGAR |
Never miss a PTGX filing.
Get an email when PTGX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.